Literature DB >> 8994752

Infection due to fluconazole-resistant Candida in patients with AIDS: prevalence and microbiology.

J R Maenza1, W G Merz, M J Romagnoli, J C Keruly, R D Moore, J E Gallant.   

Abstract

A cross-sectional study was conducted to assess the prevalence and microbiology of oral infection due to fluconazole-resistant Candida in patients with AIDS. Oral swab specimens for fungal cultures were obtained from 100 consecutive outpatients with CD4 lymphocyte counts of < 200/mm3. At least one fungal organism demonstrating in vitro resistance to fluconazole (minimum inhibitory concentration, > or = 8 micrograms/mL) was isolated from 26 (41%) of 64 patients for whom cultures were positive. When fluconazole-resistant C. albicans was isolated, in vitro resistance correlated with clinical thrush. None of 10 patients from whom only non-albicans species of Candida were isolated had active thrush. The patients from whom fluconazole-resistant Candida albicans was isolated had lower CD4 cell counts (median, 9/mm3), a greater number of treated episodes of thrush (median, 4.5), and a greater median duration of prior fluconazole treatment (231 days) than did patients from whom fluconazole-susceptible C. albicans was isolated (median CD4 cell count, 58/mm3 [P = .004]; median number of treated episodes of thrush, 2.0 [P = .001]; and median duration of prior fluconazole treatment, 10 days [P = .01]; respectively). In a multivariate analysis, the number of episodes and duration of fluconazole therapy were independent predictors of resistance.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8994752     DOI: 10.1093/clinids/24.1.28

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  28 in total

Review 1.  Antifungal prophylaxis during neutropenia and immunodeficiency.

Authors:  O Lortholary; B Dupont
Journal:  Clin Microbiol Rev       Date:  1997-07       Impact factor: 26.132

2.  Susceptibility pattern and molecular type of species-specific Candida in oropharyngeal lesions of Indian human immunodeficiency virus-positive patients.

Authors:  Ali Abdul Lattif; Uma Banerjee; Rajendra Prasad; Ashutosh Biswas; Naveet Wig; Neeraj Sharma; Absarul Haque; Nivedita Gupta; Najma Z Baquer; Gauranga Mukhopadhyay
Journal:  J Clin Microbiol       Date:  2004-03       Impact factor: 5.948

3.  Isolation of a putative Candida albicans transcriptional regulator involved in pleiotropic drug resistance by functional complementation of a pdr1 pdr3 mutation in Saccharomyces cerevisiae.

Authors:  D Talibi; M Raymond
Journal:  J Bacteriol       Date:  1999-01       Impact factor: 3.490

4.  Thirteen-year evolution of azole resistance in yeast isolates and prevalence of resistant strains carried by cancer patients at a large medical center.

Authors:  C R Boschman; U R Bodnar; M A Tornatore; A A Obias; G A Noskin; K Englund; M A Postelnick; T Suriano; L R Peterson
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

5.  A phase 2, randomized, double-blind, multicenter trial to evaluate the safety and efficacy of three dosing regimens of isavuconazole compared with fluconazole in patients with uncomplicated esophageal candidiasis.

Authors:  J Viljoen; N Azie; A-H Schmitt-Hoffmann; M Ghannoum
Journal:  Antimicrob Agents Chemother       Date:  2015-01-05       Impact factor: 5.191

6.  Azole resistance of Candida glabrata in a case of recurrent fungemia.

Authors:  Brunella Posteraro; Mario Tumbarello; Marilena La Sorda; Teresa Spanu; Enrico Maria Trecarichi; Flavia De Bernardis; Giancarlo Scoppettuolo; Maurizio Sanguinetti; Giovanni Fadda
Journal:  J Clin Microbiol       Date:  2006-08       Impact factor: 5.948

Review 7.  Clinical, cellular, and molecular factors that contribute to antifungal drug resistance.

Authors:  T C White; K A Marr; R A Bowden
Journal:  Clin Microbiol Rev       Date:  1998-04       Impact factor: 26.132

Review 8.  Immunopathogenesis of oropharyngeal candidiasis in human immunodeficiency virus infection.

Authors:  Louis de Repentigny; Daniel Lewandowski; Paul Jolicoeur
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

9.  Persistence of oropharyngeal Candida albicans strains with reduced susceptibilities to fluconazole among human immunodeficiency virus-seropositive children and adults in a long-term care facility.

Authors:  Natalya U Makarova; V V Pokrowsky; A V Kravchenko; L V Serebrovskaya; Michael J James; Michael M McNeil; Brent A Lasker; David W Warnock; Errol Reiss
Journal:  J Clin Microbiol       Date:  2003-05       Impact factor: 5.948

10.  Antifungals: need to search for a new molecular target.

Authors:  A T Sangamwar; U D Deshpande; S S Pekamwar
Journal:  Indian J Pharm Sci       Date:  2008 Jul-Aug       Impact factor: 0.975

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.